Association between Dose of Octreotide and Tumor Control in Gastroenteropancreatic Neuroendocrine Tumors Abstract #909

Introduction: Gastroenteropancreatic neuroendocrine tumors (NETs) represent a heterogeneous group of tumors. Octreotide is used in the symptom control of NETs. The PROMID study demonstrated a benefit of octreotide on disease stabilization in midgut NETs, but a survival analysis was not possible due to insufficient events.
Aim(s): To determine if dose of octreotide correlates with outcomes.
Materials and methods: We reviewed all patients who were diagnosed between 1987-2013 and treated with octreotide at the BC Cancer Agency. We compared overall survival in patients who received low v. high dose octreotide.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Sally C M Lau
Keywords: GI, NET, octreotide

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1503 Impact of Prior Somatostatin Analogue (SSA) Use on Progression-free Survival (PFS) in Patients with Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: A Secondary Analysis from the RADIANT-4 Study
Introduction: In the RADIANT-4 study, everolimus (EVE) reduced the risk of disease progression or death by 52% vs placebo (PBO; P<0.00001) in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET of lung/GI tract.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Roberto Buzzoni
#493 Pasireotide and Octreotide LAR Was an Effective Combination in a Patient with Small Intestinal NET with Hypokalemia and a High Level of VIP
Introduction: Small Intestinal neuroendocrine tumors (NET) are argentaffin-positive tumors that progress slowly.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Gordana Kozlovacki
#499 Effect of Everolimus on Pharmacokinetics of Octreotide LAR in Patients with Advanced Neuroendocrine Tumors: A RADIANT-2 Analysis
Introduction: In RADIANT-2 (NCT00412061), Everolimus (E) plus Octreotide LAR (O) exhibited a clinically meaningful 5.1-month improvement in progression-free survival (PFS) v. placebo plus octreotide LAR (P+O) in patients (pts) with advanced neuroendocrine tumors (NET) and a history of carcinoid syndrome.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Marianne E Pavel
#888 Capecitabine (Cp) and Somatostatine Analog (SSA) Suitable Treatment for Progressing G1-G2 Neuroendocrine Tumors (WD NET)
Introduction: Results from phase II and non-randomized trials with metronomic 5-FU in combination with SSA in well-differentiated (WD) NET are limited, and considered investigational.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Riccardo Marconcini
Keywords: capecitabine
#1495 Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis
Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Simron Singh
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.